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Abstract Atrolysin A and jararhagin are class P-III snake
venom metalloproteinases (SVMPs) with three distinct do-
mains: a metalloproteinase, a disintegrin-like and a cysteine-
rich. The metalloproteinase and the disintegrin-like domains of
atrolysin A and jararhagin contain peptide sequences that inter-
act with K2L1 integrin and inhibit the platelet responses to
collagen. Recently, the recombinant cysteine-rich domain of
atrolysin A was shown to have similar e¡ects, but the sequen-
ce(s) responsible for this is unknown. In this report, we demon-
strate two complete peptide sequences from the homologous
cysteine-rich domains of atrolysin A and jararhagin that inhibit
both platelet aggregation by collagen and adhesion of K2-ex-
pressing K562 cells to this protein. In addition, the peptide
e¡ects on platelets do not seem to involve an inhibition of
GPVI. These results identify, for the ¢rst time, sites in the
cysteine-rich domain of SVMPs that inhibit cell responses to
collagen and reveal the complexity of the potential biological
e¡ects of these enzymes with multifunctional domains.
1 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The engagement of platelet surface glycoproteins (GP)
through adhesion to exposed subendothelium and through
plasma protein-mediated aggregation is central for platelet
hemostatic plug formation. At the site of vascular damage,
platelets adhere through speci¢c membrane receptors to col-
lagen ¢bres and collagen-bound von Willebrand factor and
become activated by signals generated by these receptors.
Although many candidates have been proposed as platelet
collagen receptors, K2L1 integrin and GPVI play a pivotal
role [1].
Venoms from viperid snakes contain potent inhibitors of
platelet aggregation that speci¢cally target cell receptors for
adhesive protein ligands. The best characterised of these in-
hibitors are the RGD-containing disintegrins. These are non-
enzymatic cysteine-rich peptides which have a high a⁄nity for
the platelet KIIbL3 integrin and inhibit platelet aggregation by
blocking the binding of ¢brinogen to this receptor [2,3]. An-
other group of platelet inhibitors comprise the class P-III
snake venom metalloproteinases (SVMPs). These proteins
are soluble high molecular weight enzymes possessing an
N-terminal Znþþ-dependent catalytic domain, a non-RGD-
containing disintegrin-like domain and a C-terminal cys-
teine-rich region [4,5]. The metalloproteinase domain is re-
sponsible for the degradation of matrix proteins resulting in
disturbance of endothelial cell integrity and subsequent haem-
orrhage which is exacerbated by a disregulation of platelet
function. Indeed, atrolysin A [6] and catrocollastatin [7]
from the venom of Crotalus atrox and jararhagin [8] from
the venom of Bothrops jararaca are P-III venom metallopro-
teinases that have all been demonstrated to inhibit platelet/
collagen interactions [9^11]. Jararhagin recognises the platelet
collagen receptor K2L1 integrin [12] and cleaves its L1 subunit,
resulting in loss of platelet responses to collagen [10,13]. This
e¡ect is restricted to K2L1 integrin, since we have previously
shown that jararhagin does not a¡ect the platelet receptor
GPVI [14,15].
The speci¢city of SVMPs for integrins is likely to be deter-
mined by the structure of the disintegrin-like and the cysteine-
rich domains of P-III metalloproteinases. This is supported by
the reports that both native and recombinant proteins con-
taining such domains e¡ectively inhibit collagen-induced
platelet aggregation [16^19]. We, and others, have recently
shown that synthetic peptides based on the ECD-containing
sequences of disintegrin-like domain and also on RKKH-con-
taining sequences of enzymatic domain both e¡ectively inhibit
platelet/collagen interactions [11,20,21]. Moreover, Jia et al.
[19] have reported that the recombinant cysteine-rich domain
of atrolysin A also inhibits collagen-induced platelet aggrega-
tion. However, it is not yet known which site(s) of the domain
is (are) responsible for this e¡ect.
Here, we investigated the e¡ects on cellular responses to
collagen of a series of synthetic peptide based on the cys-
teine-rich domain of both atrolysin A and jararhagin. These
two proteins were chosen because they represent the archety-
pal P-III metalloproteinases found in most viperid venoms.
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The aim of the study was to determine whether the homolo-
gous structures in both proteins have the same activities and
therefore similar functions for all members of the P-III class
of SVMPs. Our results showed that the cysteine-rich domain
of both enzymes contains two sequences that inhibit the in-
teraction of K2L1 integrin-expressing K562 cells and platelets
with collagen. This is the ¢rst report of the identi¢cation of
speci¢c sites in the cysteine-rich domain of P-III venom metal-
loproteinases that inhibit cell/collagen interaction. This con-
¢rms a novel role for this domain in the interaction of the
P-III SVMPs with the function of the K2L1 integrin. Further-
more, these studies underscore the complex and manifold bio-
logical activities of these toxins and the pathological e¡ects
associated with envenoming.
2. Materials and methods
2.1. Peptide synthesis
The peptides for this study were synthesised on a Rainin Symphony
Peptide Synthesiser using FMOC-chemistry according to the manu-
facturer’s recommendation. Peptides were puri¢ed to homogeneity by
RP-HPLC (reversed phase high performance liquid chromatography)
and desalted by gel ¢ltration chromatography. Puri¢ed peptides were
analysed by MALDI-TOF mass spectrometry on a Perkin-Elmer DE
Pro mass spectrometer to con¢rm the correct mass of the peptide.
Puri¢ed peptides were cyclised by air oxidation of cysteinyl residues
as previously described [11]. Lyophilised peptides were dissolved in
DMSO (dimethyl sulphoxide) to a ¢nal concentration of 50 mM im-
mediately prior to use.
2.2. Reagents
Type I collagen ¢bres from equine tendon were obtained from
Horm Chemie (Munich, Germany). Prostaglandin E1 (PGE1), ADP,
thrombin, human ¢brinogen and proteinase inhibitors were purchased
from Sigma Chemical Co. (Dorset, UK). Ristocetin was obtained
from Lundbeck Ltd, UK, and puri¢ed human von Willebrand factor
(vWF) was from ICN Flow, UK. Sepharose 2B was obtained from
Pharmacia Biotechnology (Uppsala, Sweden). Immobilon-P mem-
brane from Millipore (Bedford, MA, USA), enhanced chemilumines-
cence (ECL) reagent and Hyper¢lm1, from Amersham (Buckingham-
shire, UK) were also used. Anti-phosphotyrosine (PY20 mAb)
labelled with horseradish peroxidase (PY20-HRP) was obtained
from Transduction Laboratories (Lexington, KY, USA). Polyclonal
anti-Syk antibody was purchased from Santa Cruz (Temecula, CA,
USA). Convulxin was a generous gift from Dr. C. Bon (Institut Pas-
teur, France). All other reagents and chemicals were of analytical
grade.
2.3. Platelet isolation and activation
Venous blood from healthy donors was mixed with 3.8% trisodium
citrate (9:1 v/v) and centrifuged at 125Ug for 10 min at room temper-
ature. The supernatant platelet-rich plasma (PRP) was separated. PRP
was also incubated with 1 Wg/ml PGE1 for 10 min and platelets were
separated by centrifugation for 30 min at 1,500Ug on a 25/34% al-
bumin density gradient at room temperature and harvested from be-
tween the two albumin layers. The platelets were then gel-¢ltered on a
Sepharose 2B column as described before [22]. Platelets either in PRP,
or as washed suspensions, were diluted to the ¢nal concentration of
2.5U108 cells/ml. Platelet aggregation was initiated by adding the
aggregating agent and all aggregation patterns were recorded at
37‡C over 4 min, under constant stirring in an aggregometer at
1000 rpm.
2.4. Platelet protein tyrosine phosphorylation and Western blotting
To analyse protein phosphorylated on tyrosine, unstimulated or
stimulated platelets were pelleted and lysed with cold radioimmuno-
precipitation assay (RIPA) bu¡er (158 mM NaCl, 1 mM EGTA, 1%
Triton X-100, 1% sodium deoxycholate, 0.1% SDS, in 10 mM Tris^
HCl pH 7.2, containing 1 mM sodium vanadate, 1 mM phenylmetha-
nesulfonyl £uoride, 10 Wg/ml leupeptin and 100 units/ml aprotinin) for
30 min at 4‡C. Lysates (25 Wl) were mixed with the same volume of
sample bu¡er, boiled for 3 min and electrophoresed by sodium do-
decyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) on a
10% polyacrylamide gel under reducing conditions. After electropho-
resis, the proteins were transferred to Immobilon-P membranes for
Western blotting and blots visualised using ECL reagent.
2.5. Immunoprecipitation
Platelet lysates prepared as described above were precleared with
protein G-Sepharose beads for 1 h; antibody (1^5 Wg/ml) was added
and the mixtures incubated overnight at 4‡C. The immune complexes
Fig. 1. Peptides based on the cysteine-rich region of atrolysin A and jararhagin. The full sequences of the cysteine-rich regions of atrolysin A
[6] and jararhagin [8] are shown together with the designed peptides derived from these sequences. The shaded areas depict the active sequences.
Peptides were screened for their ability to inhibit platelet aggregation with collagen. Scrambled peptides (HQCALNTVNTWGVAYSDPAVC
and VKCNFADCRVLFNLG) were constructed based on the active sequences only.
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were subsequently precipitated on protein G-Sepharose beads for 1 h
at 4‡C. Beads were washed four times in 1URIPA bu¡er and the
samples electrophoresed in 10% polyacrylamide gels before Western
blotting as described above.
2.6. Cell adhesion studies
Adhesion studies of cultured cells labelled with 5-chloromethyl £u-
orescein diacetate (CMFDA) were performed as described previously
[23]. Brie£y, collagen type I (Chemicon Inc.) was immobilised on a 96-
well microtitre plate (Falcon, Pittsburgh, PA) in 0.02 N CH3COOH
solution, overnight at 4‡C. Wells were blocked with 1% BSA in
Hank’s balanced salt solution (HBSS) containing 3 mM MgCl2. The
cells were labelled with £uorescein by incubation at 37‡C for 15 min
with 12.5 WM CMFDA in HBSS containing 3 mM MgCl2. Cells were
freed from unbound ligand by washing with the same bu¡er. Labelled
cells (1U105/sample) were added to the wells in the presence or ab-
sence of inhibitors and incubated at 37‡C for 30 min. Unbound cells
were removed by aspiration, the wells were washed, and bound cells
were lysed by adding 0.5% Triton X-100. The standard curve was
prepared simultaneously on the same plate using known concentra-
tions of labelled cells. The plates were read using a Cyto£uor 2350
£uorescence plate reader (Millipore, Bedford, MA, USA) at an exci-
tation wavelength of 485 nm using a 530 nm emission ¢lter.
3. Results and discussion
3.1. Identi¢cation of speci¢c sequences in the cysteine-rich
domains of atrolysin A and jararhagin that inhibit
platelet aggregation by collagen
In previous studies we demonstrated that the cysteine-rich
domain of a P-III venom metalloproteinase is capable of in-
hibiting collagen-induced platelet aggregation [19]. In order to
localise a region in the P-III metalloproteinase cysteine-rich
domain supporting that activity, we designed and synthesised
a panel of peptides spanning the complete cysteine-rich do-
mains of atrolysin A and jararhagin. The peptides with bio-
logical activity identi¢ed in this study are shown in Fig. 1.
Two regions of the cysteine-rich domain of both proteins
showed inhibitory activity on platelet aggregation with colla-
gen (Fig. 2), while scrambled sequences of these peptides were
inactive and therefore used as controls. Furthermore, the ac-
tive peptides did not inhibit platelet aggregation with either
0.05 units/ml thrombin, 12.5 mg/ml ristocetin in the presence
of 5 Wg/ml vWF, or 2 WM ADP in the presence of 200 Wg/ml
¢brinogen. This corroborated earlier observations of the se-
lective inhibition of collagen-induced platelet aggregation by
the recombinant cysteine-rich domain of atrolysin A [19] and,
for the ¢rst time, de¢ned the active sequences in this domain
of P-III venom metalloproteinases.
3.2. Cysteine-rich peptides do not a¡ect platelet aggregation via
the GPVI platelet receptor
As mentioned above, platelet stimulation by collagen for
induction of aggregation requires participation of the K2L1
integrin and GPVI. Several reports indicate that convulxin,
a C-type lectin from the venom of Crotalus durissus, induces
platelet aggregation via GPVI [24,25]. We therefore used con-
vulxin to examine whether GPVI still functions in peptide-
treated platelets that are unresponsive to collagen. Our results
show that the peptides HQC-atrox and VKC-atrox and HQC-
jararaca and VKC-jararaca, based on the cysteine-rich do-
mains of atrolysin A and jararhagin, respectively, had no in-
hibitory e¡ect on platelet aggregation induced by 100 ng/ml
convulxin (data not shown). These ¢ndings agree with our
previous investigation in which jararhagin-treated platelets
were responsive to convulxin [14], indicating a functional
GPVI. These results therefore indicate that the most likely
platelet receptor involved in the binding of these inhibitory
peptides was K2L1 integrin. We already hypothesised this
based on our studies with the recombinant cysteine-rich do-
main from atrolysin A [19].
3.3. Cysteine-rich peptides interfere with adhesion of
K2-K562 cells to collagen
To validate the observation that the peptides could interact
with the K2L1 integrin, we studied their e¡ects on adhesion to
collagen of K562 cells displaying this integrin. As seen in Fig.
3, active peptides based on the sequences of the cysteine-rich
Fig. 2. E¡ect of active peptides based on the cysteine-rich domains
of atrolysin A and jararhagin on platelet aggregation by collagen.
Washed platelets (2.5U108/ml) were incubated with di¡erent concen-
trations of peptides for 2 min with constant stirring. Collagen (2 Wg/
ml) was then added and platelet aggregation recorded for 4 min.
Controls with equivalent amounts of scrambled peptides were car-
ried out. The maximum aggregation in the presence of active pep-
tide was recorded for comparison with controls considered as 100%.
Results from two independent experiments with platelets from two
di¡erent donors are shown.
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regions of both atrolysin A and jararhagin displayed concen-
tration-dependent inhibition of the adhesion of K2-K562 cells
to collagen. The strongest inhibition was observed with the
HQC-jararaca and VKC-jararaca peptides, followed by the
VKC-atrox; the least potent inhibition was recorded with
HQC-atrox (Fig. 3). These results con¢rm the platelet aggre-
gation data and underscore the speci¢city of the peptides for
K2 integrin.
3.4. E¡ect of peptides on protein tyrosine phosphorylation in
collagen-stimulated platelets
In our previous studies we described the ability of jararha-
gin to fully abolish platelet responses to collagen, including
the tyrosine phosphorylation of Syk [13]. Both HQC-atrox
and VKC-atrox peptides partially inhibited protein tyrosine
phosphorylation in platelets stimulated with collagen (Fig.
4). In contrast, the corresponding jararhagin-based peptides
did not. Thus, although the cysteine-rich-based peptides in-
hibited not only platelet aggregation with collagen but also
K2-K562 cell adhesion to collagen, their e¡ects on decreasing
overall protein tyrosine phosphorylation in response to this
agonist were less pronounced. In addition, these peptides did
not speci¢cally a¡ect Syk phosphorylation in response to col-
lagen (Fig. 4). Following interaction of platelet with collagen
Syk is phosphorylated and activated after being recruited to
the complex with the Fc receptor Q-chain phosphorylated by
Src family kinases [26]. A recent review places GPVI as the
central receptor coordinating these events [27]. Therefore, the
most likely explanation of the absence of an e¡ect of these
peptides on collagen-induced Syk phosphorylation is that they
inhibited the binding of collagen to K2L1 integrin, but did not
a¡ect GPVI. This is strongly supported by previous observa-
tions that in platelets Syk phosphorylation by collagen de-
pends on the engagement of GPVI and not K2L1 integrin
[28,24,14]. However, despite preserved Syk phosphorylation,
platelet aggregation was inhibited by these peptides (Fig. 2).
Fig. 4. Inhibition of protein tyrosine phosphorylation in collagen-
stimulated platelets by atrolysin A- and jararhagin-based active pep-
tides. Resting washed platelets were treated with cysteine-rich or
control scrambled peptides (500 WM) for 2 min. Collagen (2 Wg/ml)
was then added and platelet aggregation recorded for 4 min. The re-
action mixtures were centrifuged and the pelleted cells lysed in
RIPA bu¡er. Proteins were separated by SDS^PAGE and Western
blotted using an anti-phosphotyrosine antibody. The top panel
shows phosphotyrosine blots of proteins in the whole cell lysates.
The bottom panel shows tyrosine-phosphorylated and total non-
phosphorylated immunoprecipitated Syk. These data are representa-
tive of two independent experiments with similar results.
Fig. 3. E¡ect of peptides on the adhesion of K2-K562 cells to colla-
gen. The e¡ect of synthetic peptides was tested using CMFDA-la-
belled K562 cells transfected with K2 integrin. Di¡erent concentra-
tions of peptides were incubated (30 min at 37‡C) with the cells
(1U105) in the 96-well plate coated with the collagen type I, in 100
Wl of HBSS containing 3 mM MgCl2. After washing with the same
bu¡er the adhered cells were lysed with Triton X-100 and the plate
was read using Cyto£uor 2350. Percentage inhibition was calculated
by comparison with £uorescence obtained from control sample with
scrambled peptides. Results are meansUS.D. (n=3).
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This could not be attributed to a direct e¡ect on the ¢brin-
ogen receptor KIIbL3 integrin. This receptor requires inside-
out activation for ¢brinogen binding necessary for platelet
aggregation [29] but has never been described to be a target
of P-III venom metalloproteinases [10]. Furthermore, when
platelets were preincubated with cysteine-rich peptides and
then stimulated by ADP instead of collagen to activate KIIbL3
integrin, platelet aggregation in ¢brinogen-containing suspen-
sions was fully preserved (not shown). Thus, the most likely
interpretation of our results is that in spite of collagen inter-
action with GPVI and Syk phosphorylation, aggregation can
not take place in this experimental setting without an addi-
tional signal generated by the involvement of K2L1 integrin.
Taken together, these data further con¢rm the high speci¢city
of the cysteine-rich region of atrolysin A for K2L1 integrin
observed by Jia et al. [19] and demonstrate the same function
for the cysteine-rich domain of jararhagin. Since the collagen-
binding site of K2L1 integrin resides in the I domain (amino
acids 140^349) of K2 subunit, it is likely that cysteine-rich
peptides inhibit platelet stimulation by collagen by binding
to this domain.
As regards native jararhagin, we previously observed cleav-
age of the platelet K2L1 integrin and complete abrogation of
Syk phosphorylation by this enzyme [13] in the presence of
functional GPVI, as detected by both convulxin and collagen-
related peptide [14,15]. This indicates that (a) a signal requir-
ing intact L1 subunit of the integrin may also be involved in
Syk activation or (b) that jararhagin targets also other, as yet
unidenti¢ed platelet receptor(s) crucial for Syk activation.
3.5. Cys-rich peptide sequences from jararhagin can themselves
stimulate platelet protein tyrosine phosphorylation
We also investigated whether the peptides alone would
cause any e¡ect on platelets. When the response of platelets
was monitored by aggregometer, HQC-atrox, VKC-atrox and
HQC-jararaca had no e¡ects, but VKC-jararaca peptide
caused a weak, rapidly reversible aggregation (Fig. 5).
Examination of protein tyrosine phosphorylation again
showed little or no change when platelets were treated with
the HQC-atrox and VKC-atrox (Fig. 6). In contrast, both
HQC-jararaca and VKC-jararaca caused some increase in ty-
rosine phosphorylation of several proteins as indicated by
arrows (Fig. 6), con¢rming limited platelet stimulation by
these peptides as observed with VKC-jararaca in the aggrega-
tion studies (Fig. 5).
Recently, we reported that surfaces coated with both active
and inactive jararhagin have a stimulatory e¡ect on ¢bro-
blasts similar to that of ¢brillar collagen [30]. Our platelet
studies suggest that this e¡ect may originate from the inter-
action of ¢broblast K2L1 integrin with HQC-jararaca and
VKC-jararaca sites within the cysteine-rich region of jararha-
gin. The weak stimulatory e¡ect that we observed with pep-
tides in solution could have been greatly ampli¢ed in studies
with ¢broblasts by extensive receptor crosslinking with sur-
face-bound ligands. Although these are interesting observa-
tions, their further follow-up was beyond the scope of the
present work.
In conclusion, the present study identi¢es peptide sequences
in the cysteine-rich regions of the P-III metalloproteinases
atrolysin A and jararhagin that interfere with interaction of
platelets and other cells with collagen, most likely via binding
to K2L1 integrin. Our study therefore supports and extends
observations made previously with the whole SVMPs proteins
and the recombinant atrolysin A cysteine-rich domain. Fur-
thermore, our study underscores the functional complexity of
the P-III SVMPs that may explain multiple pathological ef-
fects associated with these toxins.
Fig. 6. Platelet protein tyrosine phosphorylation following incuba-
tion with cysteine-rich peptides based on atrolysin A and jararhagin.
Platelets were stirred in the absence or presence of 500 WM peptide
for 2 min. Cells were then centrifuged, lysed and analysed for pro-
tein tyrosine phosphorylation as in Fig. 4. The arrows point to
bands with increased tyrosine phosphorylation, as compared to the
control. This is a representative blot using samples collected from
experiments carried out as described in Fig. 5.
Fig. 5. Aggregation responses of platelets to peptides alone in com-
parison to collagen. The reactions of platelets incubated with pep-
tides (500 Wg/ml) were monitored and recorded as shown. Platelets
were also stimulated with collagen (2 Wg/ml) for comparison. These
are representative results of triplicate determinations.
FEBS 27511 30-7-03
A.S. Kamiguti et al./FEBS Letters 549 (2003) 129^134 133
Acknowledgements: We thank the Wellcome Trust of Great Britain
for support.
References
[1] Watson, S.P. and Gibbins, J.M. (1998) Immunol. Today 19, 260^
264.
[2] Huang, T-F., Holt, J.C., Lukasiewcz, H. and Niewiarowski, S.
(1987) J. Biol. Chem. 262, 16157^16163.
[3] Niewiarowski, S., Maclane, M.A., Kloksewiak, M. and Stewart,
G.J. (1994) Semin. Hematol. 31, 289^300.
[4] Hite, L.A., Shannon, J..D., Bjarnason, J.B. and Fox, J.W. (1992)
Biochemistry 31, 6203^6211.
[5] Bjarnason, J.B. and Fox, J.W. (1994) Pharmacol. Ther. 62, 325^
372.
[6] Hite, L.A., Jia, L-G., Bjarnason, J.B. and Fox, J.W. (1994) Arch.
Biochem. Biophys. 308, 182^191.
[7] Smith, J.B., Dangelmaier, C. and Selak, M. (1991) FEBS Lett.
283, 307^310.
[8] Paine, M.J.I., Desmond, H.P., Theakston, R.D.G. and Cramp-
ton, J.M. (1992) J. Biol. Chem. 267, 22869^22876.
[9] Zhou, Q., Dangelmaier, C. and Smith, J.B. (1996) Biochem. Bio-
phys. Res. Commun. 219, 720^726.
[10] Kamiguti, A.S., Hay, C.R.M. and Zuzel, M. (1996) Biochem. J.
320, 635^641.
[11] Jia, L.-G., Wang, X.-M., Shannon, J.B., Bjarnason, J.B. and
Fox, J.W. (1997) J. Biol. Chem. 272, 13094^13102.
[12] De Luca, M., Ward, C.M., Ohmori, K., Andrews, R.K. and
Berndt, M.C. (1995) Biochem. Biophys. Res. Comm. 206, 570^
575.
[13] Kamiguti, A.S., Markland, F.S., Zhou, Q., Laing, G.D., Theak-
ston, R.D.G. and Zuzel, M. (1997) J. Biol. Chem. 272, 32599^
32605.
[14] Kamiguti, A.S., Theakston, R.D.G., Watson, S.P., Bon, C.,
Laing, G.D. and Zuzel, M. (2000) Arch. Biochem. Biophys.
374, 356^362.
[15] Hers, I., Berlanga, O., Tiekstra, M.J., Kamiguti, A.S., Theak-
ston, R.D.G. and Watson, S.P. (2000) Eur. J. Biochem. 267,
2088^2097.
[16] Zhou, Q., Smith, J.B. and Grossman, M.H. (1995) Biochem. J.
307, 411^417.
[17] Usami, Y., Fujimura, Y., Miura, S., Shima, H., Yoshida, E.,
Yoshioka, A., Hirano, K., Suzuki, M. and Titani, K. (1994) Bio-
chem. Biophys. Res. Commun. 201, 331^339.
[18] Moura-da-Silva, A.M., Linica, A., Della-Casa, M.S., Kamiguti,
A.S., Ho, P.L., Crampton, J.M. and Theakston, R.D.G. (1999)
Arch. Biochem. Biophys. 369, 295^301.
[19] Jia, L-G., Wang, X-M., Shannon, J.D., Bjarnason, J.B. and Fox,
J.W. (2000) Arch. Biochem. Biophys. 373, 281^286.
[20] Kamiguti, A.S., Moura-da-Silva, A.M., Laing, G.D., Knapp, T.,
Zuzel, M., Crampton, J.M. and Theakston, R.D.G. (1997) Bio-
chim. Biophys. Acta 1335, 209^217.
[21] Ivaska, J., Kapyla, J., Pentikainen, O., Ho¡ren, A.M., Hermo-
nen, J., Huttunen, P., Johnson, M.S. and Heino, J. (1999) J. Biol.
Chem. 274, 3513^3521.
[22] Timmons, S. and Hawiger, J. (1989) Methods Enzymol. 169, 11^
21.
[23] Marcinkiewcz, C., Lobb, R.R., Marcinkiewicz, M.M., Daniel,
J.L., Smith, J.B., Dangelmaier, C., Weinreb, P.H., Beacham,
D.A. and Niewiarowski, S. (2000) Biochemistry 39, 9859^9867.
[24] Polgar, J., Clemetson, J.M., Kehrel, B.E., Wiedemann, M., Mag-
nenat, E.M., Wells, T.N.C. and Clemetson, K.J. (1997) J. Biol.
Chem. 272, 13576^13583.
[25] Cicmil, M., Thomas, J.M., Sage, T., Barry, F.A., Leduc, M.,
Bon, C. and Gibbins, J.M. (2000) J. Biol. Chem. 275, 27339^
27347.
[26] Gibbins, J., Asselin, J., Farndale, R., Barnes, M., Law, C.L. and
Watson, S.P. (1996) J. Biol. Chem. 271, 18095^18099.
[27] Nieswandt, B. and Watson, S.P. (2003) Blood 102, 449^461.
[28] Ichinobe, T., Takayama, H., Ezumi, Y., Arai, M., Yamamoto, N.,
Takahashi, Y. and Okuma, M. (1997) J. Biol. Chem. 272, 63^68.
[29] Shattil, S.J. (1999) Thromb. Haemost. 82, 318^325.
[30] Zigrino, P., Kamiguti, A.S., Eble, J., Drescher, C., Nischt, R.,
Fox, J.W. and Mauch, C. (2002) J. Biol. Chem. 277, 40528^
40535.
FEBS 27511 30-7-03
A.S. Kamiguti et al./FEBS Letters 549 (2003) 129^134134
